Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03746-x ↗Kurz gefasst
Validierungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Ruoyun Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, …. Hauptthemen laut MEDLINE: Valproic Acid, Epilepsy, Anticonvulsants, Bayes Theorem. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study aims to assess the predictive performance of published valproic acid (VPA) population pharmacokinetic (PPK) models using an external data set in Chinese adults with epilepsy or after neurosurgery. METHODS: A total of 384 concentrations from 290 Chinese adults with epilepsy or after neurosurgery were used for external validation. Data on published VPA PPK models were extracted from the literature. Prediction-based diagnostics (such as F20 and F30), simulation-based diagnostics, and Bayesian forecasting were used to evaluate the predictability of models. RESULTS: The results of prediction-based diagnostics of all models were unsatisfactory. Models B, F, and H showed the best prediction performance in simulation-based diagnostics and Bayesian forecasting, demonstrating superior precision and accuracy. Bayesian forecasting demonstrated significant improvements in the model predictability. CONCLUSION: The published PPK models showed extensive variation in predictive performance for extrapolation among Chinese adults with epilepsy or after neurosurgery patients. Fixed parameters of Vd and Ka in the PPK modeling of VPA might be the reason for the unsatisfied predictive performance. Bayesian forecasting significantly improved model predictability and may help to individualize VPA dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China.
- Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
- Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China. 1022zzg@sina.com.
- Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China. 1022zzg@sina.com.
- Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing, 100070, People's Republic of China. meishenghui1983@126.com.
- Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University, Beijing, China. meishenghui1983@126.com.
Zitieren
APA
Wu, R., Li, K., Zhao, Z., & Mei, S. (2024). Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03746-x
Vancouver
Wu R, Li K, Zhao Z, Mei S. Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03746-x
BibTeX
@article{Wu2024,
author = {Wu, Ruoyun and Li, Kai and Zhao, Zhigang and Mei, Shenghui},
title = {Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03746-x}
}
EUVIMED